MINIREVIEW

Asthma, Viruses, and Nitric Oxide (44354)

SCHERER P. SANDERS¹

Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland

Abstract. Over the last two decades there has been a worldwide increase in the morbidity and mortality associated with asthma, a chronic inflammatory disease of the airways. There is a growing body of evidence that suggests there is an association between upper respiratory viral infections, particularly rhinovirus infections, and asthma exacerbations. Virally induced airways hyperreactivity has been associated with elevated numbers of inflammatory cells in the bronchial mucosa. Upon virus infection, respiratory epithelial cells produce proinflammatory cytokines, including IL-6, IL-8, RANTES, and GM-CSF, which could contribute to the increased inflammatory cell recruitment noted in the airways. Whether or not a viral infection triggers an asthma attack may depend upon many factors, including the types of inflammatory cells recruited to the airways, the viral load, and variations in the host antiviral response. There is evidence to support the idea that eosinophils from asthmatic and symptomatic atopic subjects may be primed to respond to chemotactic cytokines produced by infected epithelial cells. Rhinovirus infections may therefore enhance airway eosinophilia in asthmatics, leading to airway hyperresponsiveness and impaired pulmonary function. Nitric oxide is a potent inhibitor of both rhinovirus-induced cytokine production and viral replication and may play an important role in the host response to viral infections. Based upon these observations, we speculate that nitric oxide donors may represent a novel therapeutic approach for the treatment of rhinovirus infections and viral exacerbations of asthma. [P.S.E.B.M. 1999, Vol 220]

Asthma is a chronic inflammatory and obstructive disease of the airways that affects almost 15 million people, including 4 million children, in the United States (1). The annual medical costs in 1990 for patients with asthma were estimated to be about \$6 billion, with almost half of these costs due to hospitalizations for acute exacerbations (1, 2). For unknown reasons, over the last two decades there has been a worldwide increase in the morbidity and mortality associated with asthma (3, 4). Despite recent advances in the development of new therapeutic in-

terventions (5, 6), asthma remains a major cause of hospital admissions for people of all ages (7). A better understanding of the factors that cause asthma, and those that trigger asthma attacks, would have a significant impact upon health care delivery and associated costs.

Viral Exacerbations of Asthma

The symptoms of asthma include wheeze, cough, and breathlessness, and are thought to be related to the release of inflammatory mediators in the airways (8). Evidence is accumulating that viral infections may play an important role in both the development of asthma and the initiation of acute asthma attacks (9). Upper respiratory viral infections have been reported to cause wheezing in patients of all ages (10–12). For infants and children under the age of 2 years, respiratory syncytial and parainfluenza viruses have frequently been associated with wheezing episodes leading to hospitalization (9, 13). Of those individuals who experience virally induced wheezing in infancy, a subset develop per-

This work was supported by National Institutes of Health grant HL 61011.

¹ To whom requests for reprints should be addressed at Johns Hopkins Asthma and Allergy Center, 5501 Hopkins Bayview Circle, Baltimore, MD 21224-6801. E-mail: ssanders@welchlink.welch.jhu.edu

0037-9727/99/2203-0123\$10.50/0

Copyright © 1999 by the Society for Experimental Biology and Medicine

sistent asthma, suggesting that upper respiratory viral infections contribute to, but are not the sole cause of, asthma (14). Based upon current knowledge, the most significant factor implicated in the development of asthma is the genetic predisposition for an IgE-mediated response to common aeroallergens (8, 11). Interestingly, some recent data suggest that having a viral infection in early childhood may actually reduce the risk of allergen sensitization later in life (9, 15). Folkerts and colleagues have suggested that the impact of viral infection on the subsequent risk of developing asthma may depend upon the type of pathogen that infects the individual during immune development (9).

Whereas the relationship between viral infections and the development of asthma is still emerging, there is substantial data to support the concept that upper respiratory viral infections trigger asthma attacks. Among the many factors that have been linked to acute exacerbations of asthma, including exercise, exposure to drugs, allergens, and noxious gases, and gastroesophageal reflux, studies suggest that viral infections may be the most common cause (9–11, 16, 17). The association between viruses and asthma attacks was first noted during the influenza epidemic of 1957 and 1958 (18, 19). At that time it was believed that bacterial infections were also associated with exacerbations of asthma. Subsequently, numerous prospective studies confirmed a temporal relationship between asthma and viruses, but not bacteria (16, 20–25). The results of these studies indicated that 10%–50% of the acute episodes of asthma were associated with detectable viral infections, whereas the detection rate during asymptomatic periods was only 2%–3% (16, 20–22). Bacterial infections were detected in the respiratory tracts of asthmatics with equal incidence during symptomatic and asymptomatic periods (21, 24). More recent data suggest that these early studies may have underestimated the rates of viral infection, because the viruses that are frequently associated with asthma, such as rhinoviruses and coronaviruses, were elusive and difficult to culture *in vitro* (26). With the development of more sensitive techniques for the detection of viruses, such as the reverse transcription-polymerase chain reaction (RT-PCR), over 80% of spontaneous asthma exacerbations have been associated with upper respiratory viral infections (27, 28). In adults and children over 2 years old, the viruses most often identified in conjunction with the symptoms of asthma were rhinoviruses, which were detected during up to 60% of asthma attacks (7, 9, 13, 27, 28). By contrast, the detection rate for rhinoviruses in control, symptom-free subjects was $\approx$ 2% using RT-PCR (28).

Epidemiological and prospective studies have provided strong evidence that symptoms of asthma are associated with viruses, in particular rhinoviruses. The mechanisms by which upper respiratory viral infections cause airflow obstruction, the hallmark of asthma, are still uncertain. This is due partly to the fact that the relationships between viral infections and changes in lower airway physiology are complicated by many factors, including the serotype of virus,

the severity of the cold, and host defense factors (9, 29). Historically, rhinovirus colds have been viewed as infections primarily limited to the upper airways. Recent studies using RT-PCR, however, have documented that rhinovirus RNA can be detected in the lower airways during infections (30). These data are consistent with observations that upper respiratory rhinovirus infections have been associated with changes in lower airway reactivity and inflammation. Increased airway reactivity has sometimes (31), but not always, been observed in normal subjects with rhinovirus infections (32–35). Virally induced changes in lower airway reactivity are much more likely to occur in allergic (12, 35) and asthmatic individuals (33, 36, 37). Increased reactivity to methacholine (36) and histamine (12, 33, 35, 37) have been documented, beginning about 2–3 days after viral exposure and, in some cases, persisting for several weeks after the infection (12, 36).

Virally induced hyperreactivity has been correlated with elevated numbers of inflammatory cells in the lower airways (33, 38), suggesting that a bronchial mucosal inflammatory response may be one mechanism by which viral infections lead to changes in airway function. Increased numbers of inflammatory cells, including lymphocytes, eosinophils, and neutrophils, have been observed in bronchoalveolar lavage fluids (39), bronchial biopsies (33, 39), and induced sputum (38), from rhinovirus-infected individuals. Interestingly, the induced sputum from infected asthmatic subjects had increased levels of the proinflammatory eosinophil product, eosinophil cationic protein (ECP), suggesting that the eosinophils in the bronchial epithelium were activated (38). Moreover, the increased ECP correlated with a decreased PC₂₀ to histamine, reflective of an increase in airway reactivity. Studies using immunohistochemical techniques to quantify inflammatory cells in bronchial biopsies, showed increased numbers of eosinophils, which persisted in the epithelium of asthmatic, but not normal, subjects with a cold (33). Rhinovirus infections have also been shown to potentiate airway inflammation, especially eosinophilia, following antigen challenge in allergic subjects (40). The virally induced potentiation was accompanied by enhanced release of histamine persisting up to 48 hr after challenge (40). These data suggest that rhinovirus-enhanced airway hyperresponsiveness often occurs in conjunction with airway inflammation and more specifically, eosinophilic inflammation. Whether rhinoviruses cause changes in lower airway function directly by infecting the cells of the lower airways or indirectly *via* mechanisms linked to changes in the upper airways, remains to be established.

Pathogenesis of Rhinovirus Infections

To understand the pathophysiology of virally induced airway obstruction and asthma, the biochemical pathways involved in virus infections must be delineated. Since rhinoviruses have been identified as the type of virus most often associated with exacerbations of asthma, this review is primarily limited to those viruses. Studies to date have pro-

vided some important insights into the basic mechanisms of rhinovirus infections. Human rhinoviruses were discovered in 1960 as the principal causative agents of the most frequently experienced acute respiratory illness, the common cold (41–45). These viruses were classified as single, positive-stranded RNA viruses belonging to the family Picornaviridae (46–48). Since then, about 102 antigenically distinct serotypes of human rhinovirus have been isolated (48, 49). These cold viruses have been linked to exacerbations of several diseases, not only asthma, but also bronchitis, otitis media, and sinusitis (28, 46, 50).

The primary target of rhinovirus infections are the epithelial cells of the respiratory tract (51–53). *In situ* hybridization studies have detected replicating human rhinoviruses in both ciliated and nonciliated nasal epithelium (52, 53). The sites of infection were focal in nature and involved only a limited number of nasal epithelial cells. As mentioned above, recent studies have determined that rhinovirus can also be detected in cells of the lower airways (30). It is not certain how rhinovirus spreads through the airways or how many cells of the respiratory tract actually become infected. However, on a cellular level, the sequence of events in the rhinovirus infection cycle has been elucidated. The first step in the infection process involves the attachment of the virion to specific receptors in the plasma membrane of the target epithelial cell (46, 54). Human rhinoviruses have been classified into two groups, the major group that bind to cells *via* intercellular adhesion molecule-1 (ICAM-1), and the minor group that bind to cells *via* other receptors, including the low-density lipoprotein (LDL) receptor (46, 48, 49, 54–56). Following attachment, the virion undergoes a conformational change allowing delivery of the viral RNA to the cytosol of the target cell (57). Replication of the virus takes place entirely in the cytoplasm of the host cell. Using ribosomes and other protein-synthesizing molecules of the host cell, viral RNA is translated to produce a polyprotein which, following cleavage by proteinases encoded in the polyprotein, gives rise to several proteins, including a protein that initiates RNA synthesis and the necessary RNA polymerase proteins. The virus then reproduces its viral RNA, first by making complementary negative-stranded RNA molecules that consequently serve as templates for the synthesis of many positive-stranded RNA molecules. New virions are then assembled, enclosed in coat proteins, converted from noninfectious provirions to infectious virions *via* cleavage of a protein, and released from the host cell. The entire replication cycle takes about 5–10 hr for most picornaviruses (47).

Rhinovirus Infection Alters Epithelial Cell Biochemistry

The mechanisms whereby rhinovirus infection of epithelial cells leads to changes in lower airway physiology in infected individuals are the focus of intense investigation. A number of potential mechanisms by which viral infection could contribute to airway obstruction and hyperreactivity,

including changes in neural control, airway geometry, or inflammation, have been summarized in a recent review (9). Because epithelial cells are the primary hosts for rhinoviruses, it is likely that virally induced changes in the epithelial cell play an important role in the sequence of events leading to asthma exacerbations. Unlike other respiratory viruses, such as influenza, rhinoviruses are not cytotoxic to the host epithelial cell. Overt cytotoxicity has not been observed in specimens obtained from human subjects infected with rhinovirus (51, 58) or in rhinovirus-infected epithelial cell cultures (59). Infected epithelial cells may, however, contribute to airway inflammation and ultimately, the symptoms of asthma, by producing proinflammatory mediators (Table I). Studies have shown that cultures of respiratory epithelial cells infected with rhinovirus secrete elevated levels of interleukin-6 (IL-6), interleukin-8 (IL-8), interleukin-11 (IL-11), granulocyte-macrophage colony-stimulating factor (GM-CSF), and RANTES (regulated upon activation, normal T-cell expressed and presumably secreted) (59–64) (and unpublished observations). Other viruses that have been associated with asthma, such as respiratory syncytial virus and influenza virus, also induce respiratory epithelial cells to produce a similar profile of cytokines, as well as monocyte chemotactic protein-1 (MCP-1), macrophage protein-1 α (MIP-1 α), and tumor necrosis factor α (TNF α) (61, 65–74).

Nasal secretions and induced sputum from human subjects with naturally acquired or experimentally induced colds contain increased levels of many proinflammatory cytokines, and the increased levels of cytokines frequently correlate with the severity of symptoms (Table I). For instance, IL-8, a potent chemoattractant and activator for neutrophils, was elevated in asthmatic adults and children with rhinovirus infections (37, 38, 75, 76). In children with virally induced asthma, increased levels of IL-8 in nasal aspirates correlated with increased levels of neutrophil myeloperoxidase, an enzyme that produces the cytotoxic species hypohalous acid, and, in turn, with the severity of respiratory symptoms (75). Interleukin-1 (IL-1), a cytokine that enhances adhesion molecule expression and activates T lymphocytes, was increased within 24 hr after infection and

TABLE I. Virus-Induced Cytokine Production^a

Cytokine	Epithelial cells <i>in vitro</i>	Airway secretions <i>in vivo</i>
Interleukin-1	R/RSV	R/V
Interleukin-6	R/RSV/I	R/V
Interleukin-8	R/RSV/I	R/V
Interleukin-11	R/RSV/I	R/RSV/V
GMCSF	R/RSV	
RANTES	R/RSV/I	RSV/I
TNF- α	RSV/I	R/V
MCP-1	RSV	
MIP-1 α	RSV	

^a Abbreviations: R = Rhinovirus, RSV = Respiratory Syncytial Virus, I = Influenza Virus, V = Undefined upper respiratory virus.

peaked during the time of maximum illness, as reported by symptom scores (77). Increased levels of IL-11, a potent inducer of bronchial hyperresponsiveness, were highest in patients with clinically detectable wheezing and were found to correlate with bronchospasm (61). As a corollary, overexpression of IL-11 in mice was associated with marked lymphocytic infiltration of the airways, accompanied by airway remodeling and bronchial obstruction (78). In other studies, elevated levels of IL-6, a potent regulator of pulmonary inflammation and stimulator of mucosal IgA production, were detected in nasal lavage fluids and sputum from rhinovirus infected individuals (38, 60). Overexpression of IL-6, like IL-11, resulted in increased numbers of inflammatory cells, in particular, lymphocytes (79). Collectively, these studies provide support for the hypothesis that the production of proinflammatory mediators leads to changes in the airways manifested as the symptoms of disease. Virus-infected airway epithelial cells are likely an important source of these mediators; however, it should be noted that other cells in the airways may also contribute to the cytokine and chemokine milieu produced during viral infection (80).

It is clear that virus-infected epithelial cells can secrete a wide range of cytokines and chemokines that modulate inflammation, but the molecular mechanisms underlying the production of each mediator have not been elucidated fully. Moreover, although it is known that multiple types of viruses can induce cytokine release, it is not known whether the same mechanisms are involved for all viruses. For rhinovirus-induced production of IL-8 and IL-6, cytokine protein secretion is preceded by increases in steady state mRNA (60, 62, 64, 70). In some cases, it appears that transcription factors, such as nuclear transcription factor- κ B (NF- κ B), are important for the transcriptional regulation of the cytokine production (60, 64). The signal that initiates this cascade of events is a specific viral effect because inactivation of the rhinovirus by UV light significantly prevents cytokine generation (59, 62, 63). In addition, rhinovirus-induced cytokine production can also be blocked by antibodies to ICAM-1, the receptor for the major group rhinoviruses (59). However, it is still not known what step in the viral infection cycle is involved in triggering the cytokine generation. As noted earlier, the viral replication cycle for picornaviruses takes about 5–10 hr from the time of viral attachment until new viruses are released from the infected cell. Since peaks in mRNA expression for cytokines such as IL-6 and IL-8 have been observed as early as 1 hr after infection, it is unlikely that the generation of these cytokines is dependent upon viral replication (62). The relationship of viral replication to the production of other epithelial-derived cytokines remains to be determined.

Virally Induced Cytokines Recruit Eosinophils

Whether or not a viral infection triggers an asthma attack may depend upon the types of inflammatory cells recruited to the airways in atopic versus nonatopic individu-

als. Nonatopic subjects or seasonal atopics out of season, when infected with rhinovirus, have increased numbers of neutrophils and lymphocytes in the nasal mucosa and nasal secretions (81–84) and decreased numbers of peripheral blood lymphocytes (82). Asthmatic subjects with rhinovirus infections have not only increased submucosal lymphocytes, but also increased epithelial eosinophils in their lower airways (33). In addition, as discussed previously, rhinovirus infections significantly potentiate the recruitment of eosinophils to the sites of allergen challenge in allergic subjects (40). Although many inflammatory cells are involved in the pathogenesis of asthma, eosinophilia has been considered a cardinal feature of asthma for decades (85–87). Increased numbers of eosinophils in peripheral blood and bronchoalveolar lavage have been reported to correlate with the degree of bronchial hyperresponsiveness (88–92). In fact, autopsy studies have suggested that eosinophilic infiltrates in the airways are frequently characteristic of end-stage asthma (89). Therefore, it follows that rhinovirus infections, by virtue of their ability to enhance airway eosinophilia, could lead to exacerbations of asthma.

Several of the cytokines produced by virally infected epithelial cells are capable of recruiting and activating eosinophils. RANTES, for example, is a member of the C-C chemokine family and one of the most potent chemoattractants for eosinophils (65, 67, 70, 93, 94). GM-CSF has multiple effects on eosinophils, and can induce adhesion molecule expression, promote eosinophil survival, and act as a cofactor for eosinophil superoxide production and degranulation (59, 66, 95, 96). Recent studies from our laboratory (unpublished observation) have shown that in addition to RANTES and GM-CSF, rhinovirus induces human epithelial cell gene expression for eotaxin, one of the most potent and specific eosinophil chemotactic factors identified to date (97, 98). Importantly, elevated levels of these cytokines have been detected in nasal and bronchoalveolar lavage fluids and have been implicated in the pathogenesis of asthma and allergy (74, 99–103). As a result, it is very possible that virally infected epithelial cells secrete cytokines and chemokines that recruit and activate eosinophils and thereby contribute to enhanced airway eosinophilia and exacerbations of asthma.

Among the many questions that remain to be answered, is why do viral infections increase eosinophils in the airways of asthmatics and allergic subjects, but not normal subjects (33). Viral infections may differentially induce cytokine production from respiratory epithelial cells, such that cells from atopics produce cytokines that effect eosinophil function, whereas normals do not. However, this is unlikely as epithelial cells from many sources produce a similar profile of cytokines when infected with rhinoviruses. The converse, however, is possible. Eosinophils from atopics and asthmatics may differ in responsiveness compared to eosinophils from normals. The idea that cells such as eosinophils can be 'primed' *in vivo* by exposure to circulating cytokines such as interleukin-5 (IL-5), interleukin-3 (IL-3),

or GM-CSF, in asthmatics, but not normals, has been suggested as a plausible explanation for the differential recruitment. Studies have shown that eosinophils from patients with asthma have increased chemotactic and chemokinetic responses compared to eosinophils from nonasthmatic subjects, suggesting that eosinophils from asthmatics are primed to respond to chemotactic stimuli (104–106). *In vitro* studies have demonstrated that cytokines such as IL-5 and GM-CSF activate eosinophils by enhancing adhesion molecule expression and increasing transendothelial and transepithelial migration (107–109). Moreover, studies from our laboratory have shown that eosinophils from nonatopic donors undergo transepithelial migration in response to chemotactic stimuli such as RANTES, only if first exposed to IL-5 (Polito and Proud, unpublished observation). It remains to be demonstrated whether these mechanisms are operating in virally induced asthma, but it is of interest that activated eosinophils have been detected in the airways of wheezing children in the emergency room (13).

Antiviral Effects of Nitric Oxide

Clearly, significant associations exist between virally induced inflammation and asthma. However, viruses do not always induce asthma attacks in every asthmatic individual. There are several explanations for this, including variations in viral load and variations in the host antiviral and immune responses. Recent studies suggest that one important component of the host antiviral response may be the ability of respiratory epithelial cells to produce nitric oxide (NO) (62). NO is a free radical molecule that mediates a broad range of important physiological processes and may act as a vasodilator, neurotransmitter, antimicrobial, or immune regulator (110–115). There are three isoforms of the enzyme nitric oxide synthase (NOS) that produce NO: Type I or neuronal NOS (nNOS), type II or inducible NOS (iNOS), and type III or constitutive NOS (cNOS) (116, 117). It has been reported that all three types are produced by epithelial cells, although evidence from immunohistochemical studies of airway and lung tissues suggest that iNOS expression usually predominates *in vivo* (118–121). High concentrations of nitric oxide have been detected in air derived from the nasal airways (122). In fact, there is a continuous production of NO in these airways and it has been suggested that the purpose is to act as an antimicrobial agent and maintain sterility in the human sinuses (122, 123).

The role of NO in asthma is currently unclear. Interestingly, transbronchial biopsies from asthmatic patients have shown elevated iNOS expression compared to nonasthmatic controls (124). Not only are there elevated levels of NOS immunoreactive protein in the airways, there are also significantly higher levels of NO detected in exhaled air of asthmatics compared to normals (125, 126). The increased levels of expired NO in asthmatics can be lowered by steroid therapy (126–129) and NOS inhibitors (130, 131). In some asthmatics, NO can be increased beyond the already elevated basal levels in response to allergen (132).

The increased nitric oxide measured in expired breath from asthmatics has been shown to be derived from the lower airways (133, 134) and not the nasal sinuses. The cellular source of this nitric oxide has not yet been unequivocally identified, although studies suggest that the NO originates mainly from cells in the airway surface, such as epithelial cells, rather than the cells of the pulmonary circulation (120, 135, 136).

Due to its multiplicity of actions, NO in the lower airways has been described as both beneficial and harmful. For example, elevated levels of NO have been proposed to play a beneficial role due to the bronchodilating effects of NO (137). Conversely, NO has been reported to alter the balance between TH1 and TH2 cell types, leading to the proliferation of TH2 lymphocytes, which produce a cytokine profile that has been associated with exacerbations of asthma (138–140). There is convincing evidence in animal models and *in vitro* studies, that NO may be beneficial due to its potent antiviral properties. A wide range of viruses, including both DNA and RNA viruses, have been inhibited by the addition of chemical donors of NO or by the induction of NOS (141–147). *In vivo*, inhibitors of NOS have been shown to increase viral load and decrease survival in virus-infected mice (148–152).

Recently, we have shown for the first time that NO can inhibit both rhinovirus replication and rhinovirus-induced production of cytokines in human respiratory epithelial cells (62). Because epithelial cells lose the expression of NOS when placed in culture (119), we have used the nitric oxide donor 3-(2-hydroxy-2-nitroso-1-propylhydrazino)-1-propanamine (NONOate) that releases NO in a time-dependent manner at physiological pH. In our studies, NONOate inhibited virally induced production of several proinflammatory cytokines, including IL-8, IL-6, RANTES, and GM-CSF, in a dose-dependent fashion (62) (also unpublished observation). Possibly of even more significance was the ability of NONOate to inhibit rhinovirus replication. The inhibitory effects of NONOate, which has a half life of 76 min, were more pronounced at 4 hr than at 24 hr, suggesting that both viral replication and cytokine production resume as the compound decays. Additional evidence for the key role of NO released from NONOate was obtained from experiments showing that inactivated NONOate had no effect on viral titers or cytokine generation.

An exciting question that remains to be answered, is how does NO inhibit the virally induced cytokine production and viral replication in epithelial cells. Studies to date have shown that inhibition of cytokine production was observed when NONOate was added only during the viral exposure period, or only after viral exposure, suggesting that NO does not kill the virus directly or prevent the virus from entering the target cells (62). Furthermore, the inhibition of cytokine production occurred without reducing the levels of cytokine mRNA, suggesting that the inhibition was not due to the ability of NO to interfere with transcriptional regulation. The ability of NO to inhibit cytokines that are

generated late in the viral replication cycle may be secondary to the ability of NO to inhibit viral replication, but for cytokines, such as IL-8 and IL-6, that are induced rapidly after infection, the inhibitory effects of NO are not likely to be secondary to the inhibition of viral replication. Precedent exists in other cell types for NO to inhibit protein synthesis (143, 153), possibly by interfering with enzymes involved in energy metabolism (110, 154). Recent studies using [³⁵S]-methionine to label the proteins in epithelial cells have shown that NO-mediated inhibition of virally induced cytokine generation is a selective process and is not a result of nonspecific inhibition of protein synthesis (unpublished observation). Additional studies are underway to identify how NO is inhibiting cytokine protein synthesis in rhinovirus-infected epithelial cells. Further studies are also ongoing to delineate the mechanisms by which NONOate inhibits rhinovirus replication. We have hypothesized that the effects may be due to the ability of NO to activate antiviral pathways such as the double-stranded RNA-dependent protein kinase (155) or RNase L (156), or to inhibit one or more of the cysteine-containing proteases that are critical for viral protein production (47, 157–160).

Summary

Virally induced hyperreactivity has been correlated with elevated numbers of inflammatory cells in the lower airways and the production of proinflammatory cytokines. It has been hypothesized, and supported by *in vitro* data, that respiratory epithelial cells, the primary target of rhinovirus infections, are an important source of these proinflammatory cytokines. The key to whether or not these virally induced cytokines trigger an asthma attack may depend upon the type of inflammatory cells recruited to the airways. Evidence suggests that eosinophils from asthmatic and symptomatic atopic subjects versus normal subjects differ in responsiveness to chemotactic cytokines such as RANTES and eotaxin that may be produced by infected epithelial cells. Since eosinophils are known to play a key role in asthma, it follows that rhinovirus infections by virtue of their ability to enhance airway eosinophilia in asthmatics could lead to exacerbations of symptoms.

The relationship between viruses and asthma attacks is complex and depends upon multiple factors including viral load, type of infecting virus, and variations in the host antiviral response. Our data demonstrate that NO is a potent inhibitor of both rhinovirus-induced cytokine production and viral replication (62). Furthermore, we have recently demonstrated that rhinovirus infection can induce the expression of iNOS mRNA in primary human epithelial cells (unpublished observation). Poliovirus, another picornavirus, has also been reported to induce iNOS in human cells (161). Inductions of iNOS and the production of NO *in vivo* may represent an important host response to viral infections (162). Knowing that there is a strong relationship between upper respiratory viral infection, and particularly rhinovirus infections, and asthma exacerbations, we speculate that NO

plays an important anti-inflammatory and antiviral role in rhinovirus infections and that nitric oxide donors may represent a novel therapeutic approach for the treatment of colds and their related complications.

1. Smith DH, Malone DC, Lawson KA, Okamoto LJ, Battista C, Saunders WB. A national estimate of the economic costs of asthma. *Am J Respir Crit Care Med* **156**:787–793, 1997.
2. Weiss KB, Gergen PJ, Hodgson TA. An economic evaluation of asthma in the United States. *N Engl J Med* **326**:862–866, 1992.
3. Silverstein MD, Reed CE, O'Connell EJ, Melton LJ, O'Fallon WM, Yunginger JW. Long-term survival of a cohort of community residents with asthma. *N Engl J Med* **331**:1537–1541, 1994.
4. Lang DM, Polansky M. Patterns of asthma mortality in Philadelphia from 1969 to 1991. *N Engl J Med* **331**:1542–1546, 1994.
5. Torphy T. Phosphodiesterase isozymes: Molecular targets for novel antiasthma agents. *Am J Respir Crit Care Med* **157**:351–370, 1998.
6. Horwitz RJ, McGill KA, Busse WW. The role of leukotriene modifiers in the treatment of asthma. *Am J Respir Crit Care Med* **157**:1363–1371, 1998.
7. Johnston SL, Pattemore PK, Sanderson G, Smith S, Campbell MJ, Josephs LK, Cunningham A, Robinson BS, Myint SH, Ward ME, Tyrrell DAJ, Holgate ST. The relationship between upper respiratory infections and hospital admissions for asthma: A time-trend analysis. *Am J Respir Crit Care Med* **154**:654–660, 1996.
8. Sandford A, Weir R, Pare P. The genetics of asthma. *Am J Respir Crit Care Med* **153**:1749–1765, 1996.
9. Folkerts G, Busse WW, Nijkamp FP, Sorkness R, Gern JE. Virus-induced airway hyperresponsiveness and asthma. *Am J Respir Crit Care Med* **157**:1708–1720, 1998.
10. Busse WW, Gern JE. Viruses in asthma. *J Allergy Clin Immunol* **100**:147–150, 1997.
11. Lemanske RF, Busse WW. Asthma. *JAMA* **278**:1855–1873, 1997.
12. Lemanske RF, Dick EC, Swenson CA, Vrtis RF, Busse WW. Rhinovirus upper respiratory infection increases airway hyperreactivity and late asthmatic reactions. *J Clin Invest* **83**:1–10, 1989.
13. Duff AL, Pomeranz ES, Gelber LE, Price GW, Farris H, Hayden FG, Platts-Mills TAE, Heymann RW. Risk factors in acute wheezing in infants and children: Viruses, passive smoke, and IgE antibodies to inhalant allergens. *Pediatrics* **92**:535–540, 1993.
14. Martinez FD, Wright AL, Taussig LM, Holberg CJ, Halonen M, Morgan WJ, Associates GHM. Asthma and wheezing in the first six years of life. *N Engl J Med* **332**:133–138, 1995.
15. Shaheen SO. Changing patterns of childhood infection and the rise in allergic disease. *Clin Exp Allergy* **25**:1034–1037, 1995.
16. Pattemore PK, Johnston SL, Bardin PG. Viruses as precipitants of asthma symptoms. I. Epidemiology. *Clin Exp Allergy* **22**:325–336, 1992.
17. Bardin PG, Johnston SL, Pattemore PK. Viruses as precipitants of asthma symptoms. II. Physiology and mechanisms. *Clin Exp Allergy* **22**:809–822, 1992.
18. Podosin RL, Felton WL. The clinical picture of a Far-East influenza occurring at the 4th National Boy Scout Jamboree. *N Engl J Med* **238**:778–782, 1958.
19. Rebhan AW. An outbreak of Asian influenza in a girls' camp. *Can Med Assoc J* **77**:797–799, 1957.
20. Horn MEC, Reed SE, Taylor P. Role of viruses and bacteria in acute wheezy bronchitis in childhood: A study of sputum. *Arch Dis Child* **54**:587–592, 1979.
21. Hudgel DW, Langston LJ, Selner JC, McIntosh K. Viral and bacterial infections in adults with chronic asthma. *Am Rev Respir Dis* **120**:393–397, 1979.
22. Jennings LC, Barns G, Dawson KP. The association of viruses with acute asthma. *NZ Med J* **100**:488–490, 1987.
23. Beasley R, Coleman ED, Hermon Y, Holst PE, O'Donnell TV, Tobias M. Viral respiratory tract infection and exacerbations of asthma in adult patients. *Thorax* **43**:679–683, 1988.
24. McIntosh K, Ellis EF, Hoffman LS, Lybass TG, Eller JJ, Fulginiti VA. The association of viral and bacterial respiratory infections with

- exacerbations of wheezing in your asthmatic children. *J Pediatr* **82**:578–590, 1973.
25. Mitchell I, Inglis H, Simpson H. Viral infections in wheezy bronchitis and asthma in children. *Arch Dis Child* **51**:707–711, 1976.
 26. Larson HE, Reed SE, Tyrrell DAJ. Isolation of rhinoviruses and coronaviruses from 38 colds in adults. *J Med Virol* **5**:221–229, 1980.
 27. Johnston SL, Pattemore PK, Sanderson G, Smith S, Lampe F, Josephs L, Sympington P, O'Toole S, Myint SH, Tyrrell DA, Holgate ST. Community study of role of viral infections in exacerbations of asthma in 9–11 year old children. *Br Med J* **310**:1225–1228, 1995.
 28. Nicholson KG, Kent J, Ireland DC. Respiratory viruses and exacerbations of asthma in adults. *Br Med J* **307**:982–986, 1993.
 29. Grünberg K, Kuijpers EAP, de Klerk EPA, de Gouw HWFM, Kroes ACM, Dick EC, Sterk PJ. Effects of experimental rhinovirus 16 infection on airways hyperresponsiveness to bradykinin in asthmatic subjects *in vivo*. *Am J Respir Crit Care Med* **155**:833–838, 1997.
 30. Gern JE, Galagan DM, Jarjour NN, Dick EC, Busse WW. Detection of rhinovirus RNA in lower airway cells during experimentally induced infection. *Am J Respir Crit Care Med* **155**:1159–1161, 1997.
 31. Aquilina AT, Hall WJ, Douglas RG, Utell MJ. Airway reactivity in subjects with viral upper respiratory tract infections: The effects of exercise and cold air. *Am Rev Respir Dis* **122**:3–10, 1980.
 32. Halperin SA, Eggleston PA, Hendley JO, Suratt PM, Gröschel DHM, Gwaltney JM, Jr. Pathogenesis of lower respiratory tract symptoms in experimental rhinovirus infection. *Am Rev Respir Dis* **128**:806–810, 1983.
 33. Fraenkel DJ, Bardin PG, Sanderson G, Lampe F, Johnston SL, Holgate ST. Lower airways inflammation during rhinovirus colds in normal and asthmatic subjects. *Am J Respir Crit Care Med* **151**:879–886, 1995.
 34. Jenkins CR, Breslin ABX. Upper respiratory tract infections and airway reactivity in normal and asthmatic subjects. *Am Rev Respir Dis* **130**:879–883, 1984.
 35. Gern JE, Calhoun W, Swenson C, Shen G, Busse WW. Rhinovirus infection preferentially increases lower airway responsiveness in allergic subjects. *Am J Respir Crit Care Med* **155**:1872–1876, 1997.
 36. Cheung D, Dick EC, Timmers MC, de Klerk EPA, Spaan WJM, Sterk PJ. Rhinovirus inhalation causes long-lasting excessive airway narrowing in response to methacholine in asthmatic subjects *in vivo*. *Am J Respir Crit Care Med* **152**:1490–1496, 1995.
 37. Grünberg K, Timmers MC, Smits HH, de Klerk EPA, Dick EC, Spaan WJM, Hiemstra PS, Sterk PJ. Effects of experimental rhinovirus 16 colds on airway hyperresponsiveness to histamine and interleukin-8 in nasal lavage in asthmatic subjects *in vivo*. *Clin Exp Allergy* **27**:36–45, 1996.
 38. Grünberg K, Smits HH, Timmers MC, de Klerk EPA, Dolhain RJEM, Dick EC, Hiemstra PS, Sterk PJ. Experimental rhinovirus 16 infection: Effects on cell differentials and soluble markers in sputum in asthmatic subjects. *Am J Respir Crit Care Med* **156**:609–616, 1997.
 39. Trigg CJ, Nicholson KG, Wang JH, Ireland DC, Jordan S, Duddle JM, Hamilton S, Davies RJ. Bronchial inflammation and the common cold: A comparison of atopic and non-atopic individuals. *Clin Exp Allergy* **26**:665–676, 1996.
 40. Calhoun WJ, Dick EC, Schwartz LB, Busse WW. A common cold virus, rhinovirus 16, potentiates airway inflammation after segmental antigen bronchoprovocation in allergic subjects. *J Clin Invest* **94**:2200–2208, 1994.
 41. Gwaltney JM, Jr. The common cold. In: Mandell GL, Douglas RGJ, Bennet JE, Eds. *Principles and Practice of Infectious Diseases*. New York: John Wiley & Sons, pp429–435, 1979.
 42. Tyrrell DAJ, Parsons R. Some virus isolations from common colds. III. Cytopathic effects in tissue cultures. *Lancet* **i**:239–242, 1960.
 43. Monto AS. Epidemiology of respiratory viruses in persons with and without asthma and COPD. *Am J Respir Crit Care Med* **151**:1653–1658, 1995.
 44. Gwaltney JM, Hendley JO, Simon G, Jordan WS. Rhinovirus infections in an industrial population. I. The occurrence of illness. *N Engl J Med* **275**:1261–1268, 1966.
 45. Couch RB. Rhinoviruses. In: Fields BN, Knipe DM, Howley PM, Eds. *Fields Virology*, 3rd Ed. Philadelphia: Lippincott-Raven, pp713–734, 1996.
 46. Johnston SL, Bardin PG, Pattemore PK. Viruses as precipitants of asthma symptoms III. Rhinoviruses: Molecular biology and prospects for future intervention. *Clin Exp Allergy* **23**:237–246, 1993.
 47. Rueckert RR. Picornaviridae: The viruses and their replication. In: Fields BN, Knipe DM, Howley PM, Eds. *Fields Virology*. Philadelphia: Lippincott-Raven, pp609–654, 1996.
 48. Abraham G, Colonno RJ. Many rhinovirus serotypes share the same cellular receptor. *J Virol* **51**:340–345, 1984.
 49. Hofer F, Gruenberger M, Kowalski H, Machat H, Huettinger M, Kuechler E, Blaas D. Members of the low-density lipoprotein receptor family mediate cell entry of a minor-group common cold virus. *Proc Natl Acad Sci U S A* **91**:1839–1842, 1994.
 50. Turner BW, Cail WS, Hendley JO, Hayden FG, Doyle WJ, Sorrentino JV, Gwaltney JM Jr. Physiologic abnormalities of the paranasal sinuses during experimental rhinovirus colds. *J Allergy Clin Immunol* **90**:474–478, 1992.
 51. Turner RB, Hendley JO, Gwaltney JM Jr. Shedding of infected epithelial cells in rhinovirus colds. *J Infect Dis* **145**:849–853, 1982.
 52. Bardin PG, Johnston SL, Sanderson G, Robinson S, Pickett MA, Fraenkel DJ, Holgate ST. Detection of rhinovirus infection of the nasal mucosa by oligonucleotide *in situ* hybridization. *Am J Respir Cell Mol Biol* **10**:207–213, 1994.
 53. Arruda E, Boyle TR, Winther B, Pevear DC, Gwaltney JM Jr, Hayden FG. Localization of human rhinovirus replication in the upper respiratory tract by *in situ* hybridization. *J Infect Dis* **171**:1329–1333, 1995.
 54. Rowlands DJ. Rhinoviruses and cells: Molecular aspects. *Am J Respir Crit Care Med* **152**:S31–S35, 1995.
 55. Greve JM, Davis G, Meyer AM, Fork CP, Yost SC, Marlor CW, Kamarck ME, McClelland A. The major human rhinovirus receptor is ICAM-1. *Cell* **56**:839–847, 1989.
 56. Staunton DE, Merluzzi VJ, Rothlein R, Barton R, Marlin SD, Springer TA. A cell adhesion molecule, ICAM-1, is the major surface receptor for rhinoviruses. *Cell* **56**:849–853, 1989.
 57. Schober D, Kronenberger P, Prchla E, Blaas D, Fuchs R. Major and minor receptor group human rhinoviruses penetrate through endosomes by different mechanisms. *J Virol* **72**:1354–1364, 1998.
 58. Winther B, Brofeldt S, Christensen B, Mygind N. Light and scanning electron microscopy of nasal biopsy material from patients with naturally acquired common colds. *Acta Otolaryngol (Stockh)* **97**:309–318, 1984.
 59. Subauste MC, Jacoby DB, Richards SM, Proud D. Infection of a human respiratory epithelial cell line with rhinovirus: Induction of cytokine release and modulation of susceptibility to infection by cytokine exposure. *J Clin Invest* **96**:549–557, 1995.
 60. Zhu Z, Tang W, Ray A, Wu Y, Einarsson O, Landry ML, Gwaltney JM Jr, Elias JA. Rhinovirus stimulation of interleukin-6 *in vivo* and *in vitro*: Evidence for nuclear factor κ B-dependent transcriptional activation. *J Clin Invest* **97**:421–430, 1996.
 61. Einarsson O, Geba GP, Zhu Z, Landry M, Elias JA. Interleukin-11: Stimulation *in vivo* and *in vitro* by respiratory viruses and induction of airways hyperresponsiveness. *J Clin Invest* **97**:915–924, 1996.
 62. Sanders SP, Siekierski ES, Porter JD, Richards SM, Proud D. Nitric oxide inhibits rhinovirus-induced cytokine production and viral replication in a human respiratory epithelial cell line. *J Virol* **72**:934–942, 1998.
 63. Johnston SL, Papi A, Bates PJ, Mastronarde JG, Monick MM, Hunninghake GW. Low-grade rhinovirus infection induces a prolonged release of IL-8 in pulmonary epithelium. *J Immunol* **160**:6172–6181, 1998.
 64. Zhu Z, Tang W, Gwaltney JM Jr., Wu Y, Elias JA. Rhinovirus stimulation of interleukin-8 *in vivo* and *in vitro*: Role of NF- κ B. *Am J Physiol* **273**:L814–L824, 1997.
 65. Matsukura S, Kokubo F, Kubo H, Tomita T, Tokunaga H, Kadokura M, Yamamoto T, Kuroiwa Y, Ohno T, Suzuki H, Adachi M. Expression of RANTES by normal airway epithelial cells after influenza virus A infection. *Am J Respir Cell Mol Biol* **18**:255–264, 1998.
 66. Noah TL, Becker S. Respiratory syncytial virus-induced cytokine production by a human bronchial epithelial cell line. *Am J Physiol* **265**:L472–L478, 1993.
 67. Matsukura S, Kokubo F, Noda H, Tokunaga H, Adachi M. Expression of IL-6, IL-8, and RANTES on human bronchial epithelial cells,

- NCI-H292, induced by influenza virus A. *J Allergy Clin Immunol* **98**:1080–1087, 1996.
68. Choi AMK, Jacoby DB. Influenza virus A infection induces interleukin-8 gene expression in human airway epithelial cells. *FEBS Lett* **309**:327–329, 1992.
69. Becker S, Koren HS, Henke DC. Interleukin-8 expression in normal nasal epithelium and its modulation by infection with respiratory syncytial virus and cytokines tumor necrosis factor, interleukin-1 and interleukin-6. *Am J Respir Cell Mol Biol* **8**:20–27, 1993.
70. Olszewska-Pazdrak B, Casola A, Saito T, Alam R, Crowe SE, Mei F, Ogra PL, Garofalo RP. Cell-specific expression of RANTES, MCP-1, and MIP-1 α by lower airway epithelial cells and eosinophils infected with respiratory syncytial virus. *J Virol* **72**:4756–4764, 1998.
71. Patel JA, Kunimoto M, Sim TC, Garofalo R, Elliott T, Baron S, Ruuskanen O, Chonmaitree T, Ogra PL, Schmalstieg F. Interleukin-1 α mediates the enhanced expression of intercellular adhesion molecule-a in pulmonary epithelial cells infected with respiratory syncytial virus. *Am J Respir Cell Mol Biol* **13**:602–609, 1995.
72. Saito T, Deskin RW, Casola A, Häeberle H, Olszewska B, Ernst PB, Alam R, Ogra PL, Garofalo R. Respiratory syncytial virus induces selective production of the chemokine RANTES by upper airway epithelial cells. *J Infect Dis* **175**:497–504, 1997.
73. Elias JA, Zheng T, Einarsson O, Landry M, Trow T, Rebert N, Panuska J. Epithelial interleukin-11: Regulation by cytokines, respiratory syncytial virus and retinoic acid. *J Biol Chem* **269**:22261–22268, 1994.
74. Becker S, Reed W, Henderson FW, Noah TL. RSV infection of human airway epithelial cells causes production of the β -chemokine RANTES. *Am J Physiol* **272**:L512–L520, 1997.
75. Teran LM, Johnston SL, Schröder J-M, Church MK, Holgate ST. Role of nasal interleukin-8 in neutrophil recruitment and activation in children with virus-induced asthma. *Am J Respir Crit Care Med* **155**:1362–1366, 1997.
76. Noah TL, Henderson FW, Henry MM, Peden DB, Devlin RB. Nasal lavage cytokines in normal, allergic, and asthmatic school-age children. *Am J Respir Crit Care Med* **152**:1290–1296, 1995.
77. Proud D, Gwaltney JM Jr., Hendley JO, Dinarello CA, Gillis S, Schleimer RP. Increased levels of interleukin-1 are detected in nasal secretions of volunteers during experimental rhinovirus colds. *J Infect Dis* **169**:1007–1013, 1994.
78. Tang W, Geba GP, Zheng T, Ray P, Homr RJ, Kuhn C III, Flavell RA, Elias JA. Targeted expression of IL-11 in the murine airway causes lymphocytic inflammation, bronchial remodeling and airways obstruction. *J Clin Invest* **98**:2845–2853, 1996.
79. DiCosmo BF, Geba GP, Picarella D, Elias JA, Rankin JA, Stripp BR, Whitsett JA, Flavell RA. Airway epithelial cell expression of interleukin-6 in transgenic mice: Uncoupling of airway inflammation and bronchial hyperreactivity. *J Clin Invest* **94**:2028–2035, 1994.
80. Kelley J. Cytokines of the lung. *Am Rev Respir Dis* **141**:765–788, 1990.
81. Winther B, Farr B, Turner RB, Hendley JO, Gwaltney JM Jr., Mygind N. Histopathologic examination and enumeration of polymorphonuclear leukocytes in the nasal mucosa during experimental rhinovirus colds. *Acta Otolaryngol (Suppl)(Stockh)* **413**:19–24, 1984.
82. Levandowski RA, Ou DW, Jackson GG. Acute-phase decrease of T-lymphocyte subsets in rhinovirus infection. *J Infect Dis* **153**:743–748, 1986.
83. Levandowski RA, Weaver CW, Jackson GG. Nasal secretion leukocyte populations determined by flow cytometry during acute rhinovirus infection. *J Med Virol* **25**:423–432, 1988.
84. Naclerio RM, Proud D, Lichtenstein LM, Kagey-Sobotka A, Hendley JO, Sorrentino J, Gwaltney JM. Kinins are generated during experimental rhinovirus colds. *J Infect Dis* **157**:133–142, 1988.
85. Frigas E, Motojima S, Gleich GJ. The eosinophilic injury to the mucosa of the airways in the pathogenesis of bronchial asthma. *Eur Respir J* **4**:123s–135s, 1991.
86. Allen JN, Davis B. Eosinophilic lung diseases. *Am J Respir Crit Care Med* **150**:1423–1438, 1994.
87. Djukanovic R, Roche WR, Wilson JW, Beasley CRW, Twentyman OP, Howarth PH, Holgate ST. Mucosal inflammation in asthma. *Am Rev Respir Dis* **142**:434–457, 1990.
88. Wardlaw AJ, Dunnette S, Gleich GJ, Collins JV, Kay AB. Eosinophils and mast cells in bronchoalveolar lavage in subjects with mild asthma. *Am Rev Respir Dis* **137**:62–69, 1988.
89. Laitinen LA, Laitinen A, Heino M, Haahtela T. Eosinophilic airway inflammation during exacerbation of asthma and its treatment with inhaled corticosteroid. *Am Rev Respir Dis* **143**:423–427, 1991.
90. Horn BR, Robin ED, Theodore J, Kessel AV. Total eosinophil counts in the management of bronchial asthma. *N Engl J Med* **292**:1152–1155, 1975.
91. Durham SR, Kay AB. Eosinophils, bronchial hyperreactivity and late-phase asthmatic reactions. *Clin Allergy* **15**:411–418, 1985.
92. Taylor KJ, Luksza AR. Peripheral blood eosinophil counts and bronchial responsiveness. *Thorax* **42**:452–456, 1987.
93. Venge J, Lampinen M, Hakansson L, Rak S, Venge P. Identification of IL-5 and RANTES as the major eosinophilic chemoattractants in the human lung. *J Allergy Clin Immunol* **97**:1110–1115, 1996.
94. Wang JH, Devalia JL, Xia C, Sapsford RJ, Davies RJ. Expression of RANTES by human bronchial epithelial cells *in vitro* and *in vivo* and the effects of corticosteroids. *Am J Respir Cell Mol Biol* **14**:27–35, 1996.
95. Lopez AF, Williamson DJ, Gamble JR, Begley CG, Harlan JM, Klebanoff SJ, Waltersdorff A, Wong G, Clark SC, Vadas MA. Recombinant human granulocyte-macrophage colony-stimulating factor stimulates *in vitro* mature human neutrophil and eosinophil function, surface receptor expression, and survival. *J Clin Invest* **78**:1220–1228, 1986.
96. Owen WF Jr., Rothenberg ME, Silberstein DS, Gasson JC, Stevens RL, Austen KF. Regulation of human eosinophil viability, density, and function by granulocyte/macrophage colony-stimulating factor in the presence of 3T3 fibroblasts. *J Exp Med* **166**:129–141, 1987.
97. Garcia-Zepeda EA, Rothenberg ME, Ownbey RT, Celestin J, Leder P, Luster AD. Human eotaxin is a specific chemoattractant for eosinophil cells and provides a new mechanism to explain tissue eosinophilia. *Nat Med* **2**:449–456, 1996.
98. Ponath PD, Qin S, Ringler DJ, Clark-Lewis I, Wang J, Kassam N, Smith H, Shi X, Gonzalo J-A, Newman W, Gutierrez-Ramos J-C, Mackay CR. Cloning of the human eosinophil chemoattractant, eotaxin: Expression, receptor binding, and functioning properties suggest a mechanism for the selective recruitment of eosinophils. *J Clin Invest* **97**:604–612, 1996.
99. Berkman N, Krishnan VL, Gilbey T, Newton R, O'Connor B, Barnes PJ, Chung KF. Expression of RANTES mRNA and protein in airways of patients with mild asthma. *Am J Respir Crit Care Med* **154**:1804–1811, 1996.
100. Broide DH, Lotz M, Cuomo AJ, Coburn DH, Freeman EC, Wasserman SI. Cytokines in symptomatic asthma airways. *J Allergy Clin Immunol* **89**:958–967, 1992.
101. Alam R, York J, Boyars M, Stafford S, Grant JA, Lee J, Forsythe P, Sim T, Ida N. Increased MCP-1, RANTES, and MIP-1 α in bronchoalveolar lavage fluid of allergic asthmatic patients. *Am J Respir Crit Care Med* **153**:1398–1404, 1996.
102. Rajakulasingam K, Hamid Q, O'Brien F, Shotman E, Jose PJ, Williams TJ, Jacobson M, Barkans J, Durham SR. RANTES in human allergen-induced rhinitis: Cellular source and relation to tissue eosinophilia. *Am J Respir Crit Care Med* **155**:696–703, 1997.
103. Minshall EM, Cameron L, Lavigne F, Leung DYM, Hamilos D, Garcia-Zepeda EA, Rothenberg M, Luster AD, Hamid Q. Eotaxin mRNA and protein expression in chronic sinusitis and allergen-induced nasal responses in seasonal allergic rhinitis. *Am J Respir Cell Mol Biol* **17**:683–690, 1997.
104. Hakansson L, Carlson M, Stalenheim G, Venge P. Migratory responses of eosinophil and neutrophil granulocytes from asthmatic patients. *J Allergy Clin Immunol* **85**:743–750, 1990.
105. Hakansson L, Heinrich C, Rak S, Venge P. Priming of eosinophil adhesion in patients with birch pollen allergy during pollen season: Effect of immunotherapy. *J Allergy Clin Immunol* **99**:551–562, 1997.
106. Waringa RAJ, Koenderman L, Kok PTM, Kreukniet J, Bruijnzeel PLB. Modulation and induction of eosinophil chemotaxis by granulocyte-macrophage colony-stimulating factor and interleukin-3. *Blood* **77**:2694–2700, 1991.
107. Borish L, Rosenwasser LJ. Update on cytokines. *J Allergy Clin Immunol* **97**:719–734, 1996.

108. Ebisawa M, Yamada T, Bickel C, Klunk D, Schleimer RP. Eosinophil transendothelial migration induced by cytokines. III: Effect of the chemokine RANTES. *J Immunol* **153**:2153–2160, 1994.
109. Bochner BS, Schleimer RP. The role of adhesion molecules in human eosinophil and basophil recruitment. *J Allergy Clin Immunol* **94**:427–438, 1994.
110. Nussler AK, Billiar TR. Inflammation, immunoregulation, and inducible nitric oxide synthase. *J Leukocyte Biol* **54**:171–178, 1993.
111. Lowenstein CJ, Dinerman JL, Snyder SH. Nitric oxide: a physiologic messenger. *Ann Intern Med* **120**:227–237, 1994.
112. Harrison DG. Perspective series: Nitric oxide and nitric oxide synthases. *J Clin Invest* **100**:2153–2157, 1997.
113. Gaston B, Drazen JM, Loscalzo J, Stamler JS. The biology of nitrogen oxides in the airways. *Am J Respir Crit Care Med* **149**:538–551, 1994.
114. Kuo PC, Schroeder RA. The emerging multifaceted roles of nitric oxide. *Ann Surg* **221**:220–235, 1995.
115. Moncada S, Higgs A. The L-arginine-nitric oxide pathway. *N Engl J Med* **329**:2002–2012, 1993.
116. Nathan C, Xie QW. Nitric oxide synthase: Roles, tolls and controls. *Cell* **78**:915–918, 1994.
117. Nathan C. Nitric oxide as a secretory product of mammalian cells. *FASEB J* **6**:3051–3064, 1992.
118. Asano K, Chee CBE, Gaston B, Lilly CM, Gerard C, Drazen JM, Stamler JS. Constitutive and inducible nitric oxide synthase gene expression, regulation, and activity in human lung epithelial cells. *Proc Natl Acad Sci U S A* **91**:10089–10093, 1994.
119. Guo FH, De Raeve HR, Rice TW, Stuehr DJ, Thunnissen FB, J, Erzurum SC. Continuous nitric oxide synthesis by inducible nitric oxide synthase in normal human airway epithelium *in vivo*. *Proc Natl Acad Sci U S A* **92**:7809–7813, 1995.
120. Shaul PW, North AJ, Wu LC, Wells LB, Brannon TS, Lau KS, Michel T, Margraf LR, Star RA. Endothelial nitric oxide synthase is expressed in cultured human bronchiolar epithelium. *J Clin Invest* **94**:2231–2236, 1994.
121. Watkins DN, Peroni DJ, Basclain KA, Garlepp MJ, Thompson PJ. Expression and activity of nitric oxide synthases in human airway epithelium. *Am J Respir Cell Mol Biol* **16**:629–639, 1997.
122. Lundberg JON, Farkas-Szallasi T, Weitzberg E, Rinder J, Lidholm J, Ånggård A, Hökfelt T, Lundberg JM, Alving K. High nitric oxide production in human paranasal sinuses. *Nat Med* **1**:370–373, 1995.
123. Lundberg J. Airborne nitric oxide: Inflammatory marker and airway messenger in man. *Acta Physiol Scand Supplement* **633**:1–27, 1996.
124. Hamid Q, Springall DR, Riveros-Moreno V, Chanez P, Howarth P, Redington A, Bousquet J, Godard P, Holgate ST, Polak JM. Induction of nitric oxide synthase in asthma. *Lancet* **342**:1510–1513, 1993.
125. Kharitonov SA, Yates D, Robbins RA, Logan-Sinclair R, Shinebourne E, Barnes PJ. Increased nitric oxide in exhaled air of asthmatic patients. *Lancet* **343**:133–135, 1994.
126. Massaro AF, Gaston B, Kita D, Fanta C, Stamler JS, Drazen JM. Expired nitric oxide levels during treatment of acute asthma. *Am J Respir Crit Care Med* **152**:800–803, 1995.
127. Kharitonov SA, Rajakulasingam K, O'Connor B, Durham SR, Barnes PJ. Nasal nitric oxide is increased in patients with asthma and allergic rhinitis and may be modulated by nasal glucocorticoids. *J Allergy Clin Immunol* **58**:58–64, 1997.
128. Kharitonov SA, Yates DH, Barnes PJ. Inhaled glucocorticoids decrease nitric oxide in exhaled air of asthmatic patients. *Am J Respir Crit Care Med* **153**:454–457, 1996.
129. Kharitonov SA, Yates DH, Chung KF, Barnes PJ. Changes in the dose of inhaled steroid affect exhaled nitric oxide levels in asthmatic patients. *Eur Respir J* **9**:196–201, 1996.
130. Yates DH, Kharitonov SA, Thomas PS, Barnes PJ. Endogenous nitric oxide is decreased in asthmatic patients by an inhibitor of inducible nitric oxide synthase. *Am J Respir Crit Care Med* **154**:247–250, 1996.
131. Yates DH, Kharitonov SA, Robbins RA, Thomas PS, Barnes PJ. Effect of a nitric oxide synthase inhibitor and a glucocorticosteroid on exhaled nitric oxide. *Am J Respir Crit Care Med* **152**:892–896, 1995.
132. Kharitonov SA, O'Connor BJ, Evans DJ, Barnes PJ. Allergen-induced late asthmatic reactions are associated with elevation of exhaled nitric oxide. *Am J Respir Crit Care Med* **151**:1894–1899, 1995.
133. Massaro AF, Mehta S, Lilly CM, Kobzik L, Reilly JJ, Drazen JM. Elevated nitric oxide concentrations in isolated lower airway gas of asthmatic subjects. *Am J Respir Crit Care Med* **153**:1510–1514, 1996.
134. Kharitonov SA, Chung KF, Evans D, O'Connor BJ, Barnes PJ. Increased exhaled nitric oxide in asthma is mainly derived from the lower respiratory tract. *Am J Respir Crit Care Med* **153**:1773–1780, 1996.
135. Cremona G, Higgenbottom T, Takao M, Hall L, Bower EA. Exhaled nitric oxide in isolated pig lungs. *J Appl Physiol* **78**:59–63, 1995.
136. Kobzik L, Bredt DS, Lowenstein CJ, Drazen J, Gaston B, Sugarbaker D, Stamler JS. Nitric oxide synthase in human and rat lung: Immunocytochemical and histochemical localization. *Am J Respir Cell Mol Biol* **9**:371–377, 1993.
137. Hogman M, Frostell CG, Hedenstrom H, Hedenstierna G. Inhalation of nitric oxide modulates adult human bronchial tone. *Am Rev Respir Dis* **148**:1474–1478, 1993.
138. Curran AD. The role of nitric oxide in the development of asthma. *Int Arch Allergy Immunol* **111**:1–4, 1996.
139. Taylor-Robinson AW, Liew FY, Severin A. Regulation of the immune response by nitric oxide differentially produced by T-helper type 1 and T-helper type 2 cells. *Eur J Immunol* **24**:980–984, 1994.
140. Barnes PJ, Liew FY. Nitric oxide and asthmatic inflammation. *Immunol Today* **16**:128–130, 1995.
141. Harris N, Buller RML, Karupiah G. γ -interferon-induced, nitric oxide-mediated inhibition of vaccinia virus replication. *J Virol* **69**:910–915, 1995.
142. Croen KD. Evidence for an antiviral effect of nitric oxide: Inhibition of herpes simplex virus type 1 replication. *J Clin Invest* **91**:2446–2452, 1993.
143. Karupiah G, Harris N. Inhibition of viral replication by nitric oxide and its reversal by ferrous sulfate and tricarboxylic acid cycle metabolites. *J Exp Med* **181**:2171–2179, 1995.
144. Bi Z, Reiss CS. Inhibition of vesicular stomatitis virus infection by nitric oxide. *J Virol* **69**:2208–2213, 1995.
145. Lowenstein CJ, Hill SL, Lafond-Walker A, Wu J, Allen G, Landavere M, Rose NR, Herskowitz A. Nitric oxide inhibits viral replication in murine myocarditis. *J Clin Invest* **97**:1837–1843, 1996.
146. Komatsu T, Bi Z, Reiss CS. Interferon- γ -induced type I nitric oxide synthase activity inhibits viral replication in neurons. *J Neuroimmunol* **68**:101–108, 1996.
147. Reiss CS, Komatsu T. Does nitric oxide play a critical role in viral infections? *J Virol* **72**:4547–4551, 1998.
148. Akarid K, Sinet M, Desforges B, Gougerot-Pocidalo MA. Inhibitory effect of nitric oxide on the replication of a murine retrovirus *in vitro* and *in vivo*. *J Virol* **69**:7001–7005, 1995.
149. Lin Y-L, Huang Y-L, Ma S-H, Yeh C-T, Chiou S-Y, Chen L-K, Liao C-L. Inhibition of Japanese encephalitis virus infection by nitric oxide: Antiviral effect of NO on RNA virus replication. *J Virol* **71**:5227–5235, 1997.
150. Tucker PC, Griggin DE, Choi S, Bul N, Wesselingh S. Inhibition of nitric oxide synthase increases the mortality in Sindbis virus encephalitis. *J Virol* **70**:3972–3977, 1996.
151. Adler H, Beland JL, Del-Pan NC, Kobzik L, Brewer JP, Martin TR, Rimm I. Suppression of herpes simplex virus type 1 (HSV-1)-induced pneumonia in mice by inhibition of inducible nitric oxide synthase (iNOS, NOS-2). *J Exp Med* **185**:1533–1540, 1997.
152. Karupiah G, Xie Q-W, Buller RML, Nathan C, Duarte C, MacMicking JD. Inhibition of viral replication by interferon- γ -induced nitric oxide synthase. *Science* **261**:1445–1448, 1993.
153. Curran RD, Ferrari FK, Kispert PH, Stadler J, Stuehr DJ, Simmons RL, Billiar TR. Nitric oxide and nitric oxide-generating compounds inhibit hepatocyte protein synthesis. *FASEB J* **5**:2085–2092, 1991.
154. Stadler J, Curran RD, Ochoa JB, Harbreacht BG, Hoffman RA, Simmons RL, Billiar TR. Effect of endogenous nitric oxide on mitochondrial respiration of rat hepatocytes *in vitro* and *in vivo*. *Arch Surg* **126**:186–191, 1991.
155. de Haro C, Méndez R, Santoyo J. The eIF-2 α kinases and the control of protein synthesis. *FASEB J* **10**:1378–1387, 1996.
156. Samuel CE. Antiviral actions of interferon: Interferon-regulated cellular proteins and their surprisingly selective antiviral activities. *Virology* **183**:1–11, 1991.

157. Stamler JS, Singel DJ, Loscalzo J. Biochemistry of nitric oxide and its redox-activated forms. *Science* **258**:1898–1902, 1992.
158. Hambidge S, Sarnow P. Translational enhancement of the poliovirus 5' noncoding region mediated by virus-encoded polypeptide 2A. *Proc Natl Acad Sci U S A* **89**:10272–10276, 1992.
159. Kräusslich HG, Nicklin MJ, Toyoda H, Etchison D, Wimmer E. Poliovirus protease 2A induces cleavage of eukaryotic initiation factor 4F polypeptide p220. *J Virol* **61**:1478–1487, 1987.
160. Clark ME, Lieberman PM, Berk AJ, Dasgupta A. Direct cleavage of human TATA-binding protein by poliovirus protease 3C *in vivo* and *in vitro*. *Mol Cell Biol* **13**:1232–1237, 1993.
161. Lopez-Guerrero JA, Carrasco L. Effect of nitric oxide on poliovirus infection of two human cell lines. *J Virol* **72**:2538–2540, 1998.
162. Majano PL, Garcia-Monzon C, Lopez-Cabrera M, Lara-Pezzi E, Fernandez-Ruiz E, Garcia-Iglesias C, Borque MJ, Moreno-Otero R. Inducible nitric oxide synthase expression in chronic viral hepatitis: Evidence for a virus-induced gene upregulation. *J Clin Invest* **101**:1343–1352, 1998.